Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

TT-10-loaded nanoparticles enhance cardiac function in murine model of myocardial infarction

Nov. 5, 2021

New PKP2-based gene therapy for ARVC treatment

Oct. 29, 2021

Targeting IKK-beta in cardiac fibroblasts may protect against heart failure

Oct. 28, 2021

Akebia Therapeutics presents new prolyl 4-hydroxylase inhibitors

Oct. 15, 2021

Knocking down Snai1 rescues right ventricular failure in rats by blockade of EtM transition

Oct. 15, 2021

CD38 as therapeutic target for protection against doxorubicin-induced cardiotoxicity

Oct. 14, 2021

CD39+ plasmablasts and adenosine identified as drivers of sepsis-induced long-term immunosuppression

Sep. 15, 2021

ORAI1 behind the pathogenesis of pulmonary arterial hypertension

Sep. 14, 2021

New MAP4K4 inhibitors identified for suppressing cardiac muscle cell death

Sep. 9, 2021

Altered Chkb leads to cardiomyopathy, murine model shows

Sep. 6, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...